



Biocept to Participate in Two July Investment Conferences

July 19, 2021

SAN DIEGO--(BUSINESS WIRE)--Jul. 19, 2021-- [Biocept, Inc.](https://www.biocept.com) (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, announces that Michael Nall, President and CEO, will participate at the following investment conferences:

- **Brookline Capital Markets Newport Symposium**, "*Transformative Biotech – Cancer, Rare Diseases, and Viruses*," which will feature group and one-on-one investor meetings and panel discussions with scientific and industry experts. The conference is being held in Newport, R.I. on July 26.
- **A.G.P.'s Virtual MedTech Summer Conference**, which will feature one-on-one investor meetings. The conference is being held on July 29.

The Biocept Investor Presentation is available [here](#).

About Biocept

Biocept, Inc. develops and commercializes molecular diagnostic assays that provide physicians with clinically actionable information for treating and monitoring patients diagnosed with a variety of cancers. In addition to its broad portfolio of blood-based liquid biopsy assays, Biocept has developed the CNSide™ cerebrospinal fluid (CSF) assay that detects cancer that has metastasized to the central nervous system. Biocept's patented Target Selector™ technology captures and quantitatively analyzes CSF tumor cells for tumor-associated molecular markers, using technology first developed for use in blood. Biocept also is leveraging its molecular diagnostic capabilities to offer nationwide COVID-19 RT-PCR testing to support public health efforts during this unprecedented pandemic. For more information, visit www.biocept.com. Follow Biocept on [Facebook](#), [LinkedIn](#) and [Twitter](#).

View source version on [businesswire.com](https://www.businesswire.com/news/home/20210719005137/en/): <https://www.businesswire.com/news/home/20210719005137/en/>

Investor Contact:

Jody Cain, LHA Investor Relations
Jcain@lhai.com, 310-691-7100

Media Contact:

Sampson PR Group
Andrea Sampson
asampson@sampsonprgroup.com, (562) 304-0301

Source: Biocept, Inc.